Toll-like receptor modulation in cardiovascular disease: A target for intervention?

Expert Opinion on Investigational Drugs

Volumn 15, Issue 8, 2006, Pages 857-871

  Földes, Gábor ^a,b   von Haehling, Stephan ^b   Anker, Stefan D ^b,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cardiovascular disease; Drug development; Innate immune system; Toll like receptors

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CPG 7909; CRX 527; CRX 675; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; E 5564; E 6020; ER 803022; ERITORAN; FLAGELLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIQUIMOD; ISATORIBINE; LIGAND; PLACEBO; PROTEIN DERIVATIVE; PROTEIN INHIBITOR; RESIQUIMOD; S 28690; TAK 242; TOLAMBA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 4 ANTAGONIST; TOLL LIKE RECEPTOR 5 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGY; ANGIOGENESIS; ATHEROSCLEROSIS; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; GRAFT REJECTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HEPATITIS B; HEPATITIS C; HUMAN; INNATE IMMUNITY; MOLECULAR DYNAMICS; MYOCARDIAL DISEASE; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PHLEBITIS; RECEPTOR INTRINSIC ACTIVITY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CARDIAC OUTPUT, LOW; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIGANDS; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 5;

EID: 33746839212     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.8.857     Document Type: Review

References (125)

1. LEMAITRE B, NICOLAS E, MICHAUT L, REICHHART JM, HOFFMANN JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86:973-983.
2. JANEWAY CA Jr, MEDZHITOV R: Innate immune recognition. Ann. Rev. Immunol. (2002) 20:197-216.
3. TAKEDA K, KAISHO T, AKIRA S: Toll-like receptors. Ann. Rev. Immunol. (2003) 21:335-376.
4. ZHANG D, ZHANG G, HAYDEN MS et al.: A toll-like receptor that prevents infection by uropathogenic bacteria. Science (2004) 303:1522-1526.
5. DIVANOVIC S, TROMPETTE A, ATABANI SF et al.: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP 105. Nat. Immunol. (2005) 6:571-578.
6. AKIRA S, TAKEDA K, KAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. (2001) 2:675-680.
7. JANSSENS S, BEYAERT R: Role of Toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. (2003) 16:637-646.
8. AHMAD-NEJAD P, HACKER H, RUTZ M et al.: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. (2002) 32:1958-1968.
9. HEIL F, HEMMI H, HOCHREIN H et al.: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303:1526-1529.
10. AKIRA S, UEMATSU S, TAKEUCHI O: Pathogen recognition and innate immunity. Cell (2006) 124:783-801.
11. HAYASHI F, SMITH KD, OZINSKY A et al.: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 410:1099-1103.
12. MEDZHITOV R, PRESTON-HURLBURT P, JANEWAY CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 388:394-397.
13. HEMMI H, TAKEUCHI O, KAWAI T et al.: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740-745.
14. HEINE H, LIEN E: Toll-like receptors and their function in innate and adaptive immunity. Int. Arch. Allergy Immunol. (2003) 130:180-192.
15. BEG AA: Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. (2002) 23:509-512.
16. SMILEY ST, KING JA, HANCOCK WW: Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol. (2001) 167:2887-2894.
17. WALLIN RP, LUNDQVIST A, MORE SH et al.: Heat-shock proteins as activators of the innate immune system. Trends Immunol. (2002) 23:130-135.
18. FRANTZ S, KELLY RA, BOURCIER T: Role of TLR-2 in the activation of nuclear factor κB by oxidative stress in cardiac myocytes. J. Biol. Chem. (2001) 276:5197-5203.
19. JOHNSON GB, BRUNN GJ, TANG AH, PLATT JL: Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol. (2003) 24:19-24.
20. AXTELLE T, PRIBBLE J: IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J. Endotoxin. Res. (2001) 7:310-314.
21. DUNNE A, O'NEILL LA: Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett. (2005) 579:3330-3335.
22. AKIRA S, TAKEDA K: Toll-like receptor signalling. Nat. Rev. Immunol. (2004) 4:499-511.
23. YAMAMOTO M, SATO S, HEMMI H et al.: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 301:640-643.
24. YAMAMOTO M, SATO S, HEMMI H et al.: TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat. Immunol. (2003) 4:1144-1150.
25. BIN LH, XU LG, SHU HB: TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter protein involved in TIR signaling. J. Biol. Chem. (2003) 278:24526-24532.
26. COOK DN, PISETSKY DS, SCHWARTZ DA: Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. (2004) 5:975-979.
27. IWASAKI A, MEDZHITOV R: Toll-like receptor control of the adaptive immune responses. Nat. Immunol. (2004) 5:987-995.
28. MEDZHITOV R: Toll-like receptors and innate immunity. Nat. Rev. Immunol. (2001) 1:135-145.
29. NAPOLITANI G, RINALDI A, BERTONI F, SALLUSTO F, LANZAVECCHIA A: Selected Toll-like receptor agonist combinations synergistically trigger a T helper Type 1-polarizing program in dendritic cells. Nat. Immunol. (2005) 6:769-776.
30. BAUMGARTEN G, KNUEFERMANN P, NOZAKI N et al.: In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J. Infect. Dis. (2001) 183:1617-1624.
31. HOFFMANN JA, KAFATOS FC, JANEWAY CA, EZEKOWITZ RA: Phylogenetic perspectives in innate immunity. Science (1999) 284:1313-1318.
32. ANKER SD, VON HAEHLING S: Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 90:464-470.
33. KNUEFERMANN P, VALLEJO J, MANN DL: The role of innate immune responses in the heart in health and disease. Trends Cardiovasc. Med. (2004) 14:1-7.
34. VISINTIN A, MAZZONI A, SPITZER JH et al.: Regulation of Toll-like receptors in human monocytes and dendritic cells. J. Immunol. (2001) 166:249-255.
35. ZAREMBER KA, GODOWSKI PJ: Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. (2002) 168:554-561.
36. ALIPRANTIS AO, YANG RB, WEISS DS, GODOWSKI P, ZYCHLINSKY A: The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J. (2000) 19:3325-3336.
37. SHISHIDO T, NOZAKI N, YAMAGUCHI S et al.: Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation (2003) 108:2905-2910.
38. NOZAKI N, SHISHIDO T, TAKEISHI Y, KUBOTA I: Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation (2004) 110:2869-2874.
39. CHOW JC, YOUNG DW, GOLENBOCK DT, CHRIST WJ, GUSOVSKY F: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. (1999) 274:10689-10692.
40. HOSHINO K, TAKEUCHI O, KAWAI T et al.: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. (1999) 162:3749-3752.
41. NEMOTO S, VALLEJO JG, KNUEFERMANN P et al.: Escherichia coli LPS-induced IV dysfunction: role of toll-like receptor-4 in the adult heart. Am. J. Physiol. Heart Circ. Physiol. (2002) 282:H2316-H2323.
42. ARBOUR NC, LORENZ E, SCHUTTE BC et al.: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. (2000) 25:187-191.
43. SALEH M, VAILLANCOURT JP, GRAHAM RK et al.: Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature (2004) 429:75-79.
44. SCHRODER NW, SCHUMANN RR: Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect. Dis. (2005) 5:156-164.
45. SCHWARTZ DA, COOK DN: Polymorphisms of the Toll-like receptors and human disease. Clin. Infect. Dis. (2005) 41(Suppl. 7):S403-S407.
46. KIECHL S, LORENZ E, REINDL M et al.: Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. (2002) 347:185-192.
47. MURRAY CJ, LAUER JA, HUTUBESSY RC et al.: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet (2003) 361:717-725.
48. LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420:868-874.
49. BJORKBACKA H, KUNJATHOOR VV, MOORE KJ et al.: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. (2004) 10:416-421.
50. LEINONEN M, SAIKKU P: Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect. Dis. (2002) 2:11-17.
51. DUNZENDORFER S, LEE HK, SOLDAU K, TOBIAS PS: Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS responses. FASEB J. (2004) 18:1117-1119.
52. AMEZIANE N, BEILLAT T, VERPILLAT P et al.: Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. (2003) 23:e61-e64.
53. BOEKHOLDT SM, AGEMA WR, PETERS RJ et al.: Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation (2003) 107:2416-2421.
54. LIN YC, CHANG YM, YU JM et al.: Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis (2005) 180:305-309.
55. XU XH, SHAH PK, FAURE E et al.: Toll-like receptor-4 is expressed by macrophages in routine and human lipid-rich atherosclerosic plaques and upregulated by oxidized LDL. Circulation (2001) 104:3103-3108.
56. VINK A, SCHONEVELD AH, VAN DER MEER JJ et al.: In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation (2002) 106:1985-1990.
57. FUSTER V, MORENO PR, FAYAD ZA, CORTI R, BADIMON JJ: Atherothrombosis and high-risk plaque: part I: evolving concepts. J. Am. Coll. Cardiol. (2005) 46:937-954.
58. HOLLESTELLE SC, DE VRIES MR, VAN KEULEN JK et al.: Toll-like receptor 4 is involved in outward arterial remodeling. Circulation (2004) 109:393-398.
59. METHE H, KIM JO, KOFLER S et al.: Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation (2005) 111:2654-2661.
60. SATOH M, SHIMODA Y, MAESAWA C et al.: Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int. J. Cardiol. (2006) 109(2):226-234.
61. EDFELDT K, SWEDENBORG J, HANSSON GK, YAN ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation (2002) 105:1158-1161.
62. MULLICK AE, TOBIAS PS, CURTISS LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest (2005) 115:3149-3156.
63. LEHR HA, SAGBAN TA, IHLING C et al.: Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation (2001) 104:914-920.
64. LEVY MM, FINK MP, MARSHALL JC et al.: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. (2003) 29:530-538.
65. LEFER AM: Mechanisms of cardiodepression in endotoxin shock. Circ. Shock Suppl. (1979) 1:1-8.
66. OGNIBENE FP, PARKER MM, NATANSON C, SHELHAMER JH, PARRILLO JE: Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest (1988) 93:903-910.
67. SASU S, LAVERDA D, QURESHI N, GOLENBOCK DT, BEASLEY D: Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/ p42 mitogen-activated protein kinase activation. Circ. Res. (2001) 89:244-250.
68. POLDERMAN KH, GIRBES AR: Drug intervention trials in sepsis: divergent results. Lancet (2004) 363:1721-1723.
69. RAEBURN CD, CALKINS CM, ZIMMERMAN MA et al.: Vascular cell adhesion molecule-1 expression is obligatory for endotoxin-induced myocardial neutrophil accumulation and contractile dysfunction. Surgery (2001) 130:319-325.
70. RUBIN LJ, KELLER RS, PARKER JL, ADAMS HR: Contractile dysfunction of ventricular myocytes isolated from endotoxemic guinea pigs. Shock (1994) 2:113-120.
71. BEUTLER B: TLR4 as the mammalian endotoxin sensor. Curr. Top. Microbiol. Immunol. (2002) 270:109-120.
72. SCHRODER NW, HERMANN C, HAMANN L et al.: High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J. Mol. Med. (2003) 81:368-372.
73. SATOH M, NAKAMURA M, AKATSU T et al.: Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin. Sci. (Load.) (2003) 104:577-584.
74. MARTY RR, DIRNHOFER S, MAUERMANN N et al.: MyD88 signaling controls autoimmune myocarditis induction. Circulation (2006) 113:258-265.
75. TRIANTAFILOU K, ORTHOPOULOS G, VAKAKIS E et al.: Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol. (2005) 7:1117-1126.
76. McMURRAY JJ, STEWART S: Epidemiology, aetiology, and prognosis of heart failure. Heart (2000) 83:596-602.
77. ANKER SD, VON HAEHLING S: Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 90:464-470.
78. FRANTZ S, KOBZIK L, KIM YD et al.: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest. (1999) 104:271-280.
79. NIEBAUER J, VOLK HD, KEMP M et al.: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 353:1838-1842.
80. BIRKS EJ, FELKIN LE, BANNER NR et al.: Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J. Heart Lung Transplant. (2004) 23:228-235.
81. TORRE-AMIONE G, KAPADIA S, BENEDICT C et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. (1996) 27:1201-1206.
82. ROSSIGNOL DP, LYNN M: Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J. Endotoxin. Res. (2002) 8:483-488.
83. ROSSIGNOL DP, WASAN KM, CHOO E et al.: Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob. Agents Chemother. (2004) 48:3233-3240.
84. LYNN M, ROSSIGNOL DP, WHEELER JL et al.: Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. (2003) 187:631-639.
85. LYNN M, WONG YN, WHEELER JL et al.: Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia. J. Pharmacol. Exp. Ther. (2004) 308:175-181.
86. WASAN KM, SIVAK O, COTE RA et al.: Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations. Antimicrob. Agents Chemother. (2003) 47:2796-2803.
87. YAMADA M, ICHIKAWA T, II M et al.: Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J. Med. Chem. (2005) 48:7457-7467.
88. CLUFF CW, BALDRIDGE JR, STOVER AG et al.: Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. (2005) 73:3044-3052.
89. HAWKINS LD, ISHIZAKA ST, McGUINNESS P et al.: A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J. Pharmacol. Exp. Ther. (2002) 300:655-661.
90. DA SILVA CJ, SOLDAU K, CHRISTEN U, TOBIAS PS, ULEVITCH RJ: Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J. Biol. Chem. (2001) 276:21129-21135.
91. YANG RB, MARK MR, GRAY A et al.: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature (1998) 395:284-288.
92. VERBON A, DEKKERS PE, TEN HOVE T et al.: IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J. Immunol. (2001) 166:3599-3605.
93. GENTH-ZOTZ S, VON HAEHLING S, BOLGER AP et al.: The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-α in patients with chronic heart failure. Eur. J. Heart Fail. (2005).
94. REINHART K, GLUCK T, LIGTENBERG J et al.: CD14 receptor occupancy in severe sepsis: results of a Phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit. Care Med. (2004) 32:1100-1108.
95. BUWITT-BECKMANN U, HEINE H, WIESMULLER KH et al.: Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur. J. Immunol. (2005) 35:282-289.
96. VON HAEHLING S, ANKER SD: Future prospects of anticytokine therapy in chronic heart failure. Expert. Opin. Investig. Drugs (2005) 14:163-176.
97. VON HAEHLING S, ANKER SD, BASSENGE E: Statins and the role of nitric oxide in chronic heart failure. Heart Fail. Rev. (2003) 8:99-106.
98. RIDKER PM, CANNON CP, MORROW D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. (2005) 352:20-28.
99. NODE K, FUJITA M, KITAKAZE M, HORI M, LIAO JK: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 108:839-843.
100. FOLDES G, VON HAEHLING S, OKONKO DO, JANKOWSKA EA, POOLE-WILSON PA, ANKER SD. HMG-CoA reductase inhibition reduces high peripheral blood monocyte Toll-like receptor 4 expression in patients with heart failure (abstract). Circulation (2005) 112:II-638.
101. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
102. + monocytes. Arterioscler. Thromb. Vasc. Biol. (2005).
103. BURDELYA LG, DIDONATO J, KRIVOKRYSENKO VI, GUROVA KV, KOGAN Y, KOMAROV PG, GUDKOV AV: NF-κB activating proteins as radioprotectants: derivatives of flagellin from Salmonella protect mice from hematopoietic and gastrointestinal radiation syndromes. International Workshop in Space Radiation Research (2004).
104. HICKS L, SHI Y, MENA J, HAMMOND C, TOMIC Y, TOMAI YA, MILLER RL, SPANER DE: The effect of a Toll Receptor-7 agonist (S28690) on the immunogenicity of chronic lymphocytic leukemia cells. Blood (2006) 104:11.
105. HORSMANS Y, BERG T, DESAGER JP et al.: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (2005) 42:724-731.
106. TESTERMAN TL, GERSTER JF, IMBERTSON LM et al.: Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. (1995) 58:365-372.
107. SAUDER DN, SMITH MH, SENTA-McMILLIAN T, SORIA I, MENG TC: Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob. Agents Chemother. (2003) 47:3846-3852.
108. SPRUANCE SL, TYRING SK, SMITH MH, MENG TC: Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis. (2001) 184:196-200.
109. KLINMAN DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. (2004) 4:249-258.
110. AGRAWAL S, KANDIMALLA ER: Role of Toll-like receptors in antisense and siRNA. Nat. Biotechnol. (2004) 22:1533-1537.
111. ISHII KJ, GURSEL I, GURSEL M, KLINMAN DM: Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleoddes. Curr. Opin. Mol. Ther. (2004) 6:166-174.
112. KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760.
113. AGRAWAL S, KANDIMALLA ER: Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. (2002) 8:114-121.
114. KANDIMALLA ER, YU D, AGRAWAL S: Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Opin. Mol. Ther. (2002) 4:122-129.
115. H1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. (2004) 27:460-471.
116. ROMAN M, SPIEGELBERG HL, BROIDE D, RAZ E: Gene immunization for allergic disorders. Springer Semin. Immunopathol. (1997) 19:223-232.
117. AGRAWAL DK, EDWAN J, KANDIMALLA ER et al.: Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int. Immunopharmacol. (2004) 4:127-138.
118. VOLLMER J: Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin. Biol. Ther. (2005) 5:673-682.
119. BALDRIDGE JR, McGOWAN P, EVANS JT et al.: Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. (2004) 4:1129-1138.
120. PAUL S: Technology evaluation: CpG-7909, Coley. Curr. Opin. Mol. Ther. (2003) 5:553-559.
121. HEIKENWALDER M, POLYMENIDOU M, JUNT T et al.: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. (2004) 10:187-192.
122. SWITAJ T, LASEK W: Technology evaluation: HYB-2055, Hybridon. Curr. Opin. Mol. Ther. (2005) 7:376-383.
123. STOCKFLETH E, TREFZER U, GARCIA-BARTELS C et al.: The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br. J. Dermatol. (2003) 149(Suppl. 66):53-56.
124. JONES T: Resiquimod 3M. Curr. Opin. Investig. Drugs (2003) 4:214-218.
125. METHE H, ZIMMER E, GRIMM C, NABAUER M, KOGLIN J: Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation (2004) 78:1324-1331.